Overview
- The Nobel Prize in Physiology or Medicine was awarded Monday to Karl Deisseroth, Peter Hegemann and Georg Nagel for discovering light‑gated ion channels and developing optogenetics, a method that uses light to control specific neurons.
- An expanded clinical report published in early October tested an optogenetic vision therapy in ten people with advanced retinitis pigmentosa and found increased light sensitivity in seven participants, with six meeting a predefined threshold for clinically meaningful improvement.
- The treatment works by injecting a viral vector that delivers the ChrimsonR gene to surviving retinal ganglion cells and using special goggles that convert camera images into amber light pulses to stimulate those cells and send signals through the optic nerve to the brain.
- Safety signals were acceptable within the study limits: most eye events were mild or moderate, and one transient severe event — a brief central retinal artery occlusion after injection — resolved within minutes with treatment.
- Researchers caution that gains were modest and task‑specific, required training with the goggles, did not restore reading or face recognition, and that larger trials, longer follow‑up, improved vectors and better stimulation hardware will be needed to increase function and assess broader use.